Subcutaneous omacetaxine mepesuccinate in patients with chronic phase (CP) or accelerated phase (AP) chronic myeloid leukemia (CML) resistant/intolerant to two or three approved tyrosine-kinase inhibitors (TKIs).

Franck E. Nicolini,Jeffrey H. Lipton,Hagop M. Kantarjian,Meir Wetzler,Luke P. Akard,Michele Baccarani,Adam R. Craig,Nisha Nanda,Peter D. Brown,Jorge E. Cortes

Subcutaneous omacetaxine mepesuccinate in patients with chronic phase (CP) or accelerated phase (AP) chronic myeloid leukemia (CML) resistant/intolerant to two or three approved tyrosine-kinase inhibitors (TKIs).

2017

Franck E. Nicolini
Jeffrey H. Lipton
Hagop M. Kantarjian
Meir Wetzler
Luke P. Akard
Michele Baccarani
Adam R. Craig
Nisha Nanda
Peter D. Brown
Jorge E. Cortes

6513 Background: Omacetaxine mepesuccinate (“omacetaxine”) is a first-in-class, reversible, transient inhibitor of protein elongation that facilitates tumor cell death without depending on BCR-ABL ...

Keywords:

Pathology
Programmed cell death
Cancer research
Myeloid leukemia
Omacetaxine mepesuccinate
Accelerated phase
Tyrosine kinase
Medicine
tumor cell death
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations